Business
Live Shareholder Q&A and Investor presentations
Live Shareholder Q&A and Investor presentations.
About this update from Valirx Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0185S\n ValiRx PLC\n 11 November 2021\n \n \n \n 11 November 2021\n \n ValiRx PLC (\"ValiRx\" or the \"Company\")\n \n Live Shareholder Q&A and Investor presentations\n \n \n Live Q&A: London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, invites shareholders to join the CEO, Chairman and Corporate Development Manager in a Zoom webinar on 25 November 2021 at 2pm (UK). Registration prior to the event is recommended to ensure all notifications about the webinar are received by participants. Registration details will be available on the ValiRx website closer to the event. The format will comprise a short presentation by the Company on latest developments, followed by an invitation to shareholders to activate their cameras and speak directly with the ValiRx team. A recording of the event will be available to view from the ValiRx website shortly after the event concludes.\n \n LSE Investor Presentation: CEO, Dr Suzy Dilly will also be presenting at this event on the evening of 7 December (6pm - 8pm (UK)). Prior registration is required directly with LSE, which can be accessed at https://us02web.zoom.us/webinar/register/1116364722800/WN_oBS-LVJrQJ-K9iQlDe3nMA. The format will be a short presentation and audience Q&A.\n \n Corporate Update: The Company is also pleased to inform shareholders that the entry on www.clinicaltrials.gov for the recently completed VAL201 clinical trial has now been finalised with the addition of a summary of raw data results.\n \n Dr Suzy Dilly, CEO of ValiRx commented: \"I am looking forward to joining our shareholders in further live discussions as we continue building our events schedule to achieve transparent shareholder communications. Further conversations about our recent scientific and commercial advances, as well as conversations around our emerging strategy in Women's Health are important as we wish to ensure that shareholders understand how we are intending to continue to build long term value into the Company.\"\n \n *** ENDS ***\n \n For more information, please contact:\n \n \n \n \n ValiRx plc\n \n Dr Suzanne Dilly, CEO\n \n \n \n \n Tel: +44 (0) 2476 796496\n \n \n \n www.valirx.com\n \n \n \n [email protected]\n \n \n \n \...